Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Bacillus anthracis | Anthrax lethal factor | Starlite/ChEMBL | No references |
Escherichia coli | penicillin-binding protein | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Mycobacterium tuberculosis | Possible penicillin-binding protein | Get druggable targets OG5_149948 | All targets in OG5_149948 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Onchocerca volvulus | 0.2416 | 1 | 1 | |
Plasmodium falciparum | hexokinase | 0.2416 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0768 | 0.0123 | 0.0123 |
Leishmania major | hexokinase, putative | 0.2416 | 1 | 0.5 |
Schistosoma mansoni | hexokinase | 0.2416 | 1 | 0.5 |
Loa Loa (eye worm) | hexokinase | 0.1515 | 0.4604 | 0.4604 |
Brugia malayi | Hexokinase family protein | 0.2416 | 1 | 1 |
Trypanosoma cruzi | hexokinase, putative | 0.2416 | 1 | 0.5 |
Echinococcus granulosus | hexokinase type 2 | 0.2416 | 1 | 0.5 |
Leishmania major | hexokinase, putative | 0.2416 | 1 | 0.5 |
Brugia malayi | Hexokinase family protein | 0.1515 | 0.4604 | 0.4604 |
Echinococcus granulosus | hexokinase | 0.2416 | 1 | 0.5 |
Toxoplasma gondii | hexokinase | 0.2416 | 1 | 0.5 |
Trypanosoma brucei | hexokinase | 0.2416 | 1 | 0.5 |
Loa Loa (eye worm) | nuclear receptor nhr-7B | 0.2048 | 0.7796 | 0.7796 |
Onchocerca volvulus | Steroid hormone receptor family member cnr14 homolog | 0.2098 | 0.8098 | 0.6476 |
Loa Loa (eye worm) | hypothetical protein | 0.1648 | 0.5396 | 0.5396 |
Trypanosoma brucei | hexokinase | 0.2416 | 1 | 0.5 |
Onchocerca volvulus | 0.2416 | 1 | 1 | |
Loa Loa (eye worm) | hypothetical protein | 0.0768 | 0.0123 | 0.0123 |
Entamoeba histolytica | hexokinase 1 | 0.2416 | 1 | 0.5 |
Loa Loa (eye worm) | hexokinase type II | 0.2416 | 1 | 1 |
Loa Loa (eye worm) | hexokinase | 0.2416 | 1 | 1 |
Loa Loa (eye worm) | hexokinase | 0.2416 | 1 | 1 |
Echinococcus multilocularis | hexokinase type 2 | 0.2416 | 1 | 0.5 |
Treponema pallidum | hexokinase (hxk) | 0.2416 | 1 | 0.5 |
Trypanosoma brucei | hexokinase, putative | 0.2416 | 1 | 0.5 |
Brugia malayi | hexokinase type II | 0.0768 | 0.0123 | 0.0123 |
Trypanosoma cruzi | hexokinase, putative | 0.2416 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase | 0.2416 | 1 | 0.5 |
Entamoeba histolytica | hexokinase 2 | 0.2416 | 1 | 0.5 |
Echinococcus granulosus | hexokinase | 0.2416 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase | 0.2416 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.2003 | 0.7527 | 0.7527 |
Echinococcus granulosus | hexokinase | 0.2416 | 1 | 0.5 |
Brugia malayi | nuclear hormone receptor | 0.2048 | 0.7796 | 0.7796 |
Echinococcus multilocularis | hexokinase | 0.2416 | 1 | 0.5 |
Plasmodium vivax | hexokinase, putative | 0.2416 | 1 | 0.5 |
Onchocerca volvulus | 0.2416 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
AC50 (functional) | 35.17 uM | PubChem BioAssay. Identification of Inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_Dose_CherryPick_Activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 1.5849 um | PUBCHEM_BIOASSAY: qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent). (Class of assay: confirmatory) [Related pubchem assays: 1002 (Confirmation Concentration-Response Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent)), 585 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent) - a screen old NIH MLSMR collection), 584 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent) - a screen of the old NIH MLSMR collection), 1003 (Confirmation Cuvette-Based Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent))] | ChEMBL. | No reference |
Potency (functional) | = 7.9433 um | PUBCHEM_BIOASSAY: qHTS Assay for Anthrax Lethal Toxin Internalization. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 16.5113 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 18.526 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 23.7781 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 25.1189 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 25.1189 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Human Jumonji Domain Containing 2E (JMJD2E). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 25.1189 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 25.1189 uM | PUBCHEM_BIOASSAY: qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488813] | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.